NCT04266028View on ClinicalTrials.gov

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Birch Pollen Allergy
Interventions
BIOLOGICAL

DM-101

DM-101 administered by subcutaneous (SC) injection

BIOLOGICAL

Placebo to match DM-101

Placebo to match DM-101 administered by SC injection

Trial Locations (1)

Unknown

Clinical Research Services Turku, Turku

Sponsors

Lead Sponsor

Desentum Oy
All Listed Sponsors
lead

Desentum Oy

INDUSTRY